Estimulación ovárica controlada con hormona foliculoestimulante recombinante de acción prolongada frente a hormona foliculoestimulante recombinante diaria: experiencia en nuestro centro

Abstract

Introduction

Corifollitropin alpha helps in reducing the number of injections per cycle, which could result in a decrease in the emotional burden and the subsequent improved adherence to treatment. The aim of this study is to compare the results of ovarian stimulation treatment for IVF using long-acting recombinant FSH and recombinant FSH daily administration in patients with normal response prognosis.

Material and methods

A retrospective study was conducted between 2013 and 2014 on 310 patients with normal response prognosis undergoing their first cycle of ICSI. A comparative study was performed between two stimulation protocols: the study group was composed of 125 patients, in whom stimulation was performed with corifollitropin alpha, followed, if necessary, by FSH-r from the eighth day. The control group was composed of 185 patients, who received FSH-r daily from the beginning. Pituitary braking to prevent spontaneous ovulation was done with GnRH antagonist from the 5th day of stimulation, after visualisation of a follicle> 14 mm. We compared the results of the stimulation cycle by analysing the days of stimulation, the number of follicles between 14-16 mm and greater than 16 mm, oestradiol, and the thickness of the endometrial line at the time of induction of ovulation, the number of oocytes obtained and the maturational stage, ICSI fertilization rate and the number of embryos obtained, embryos transferred, discarded and cryopreserved. A comparison was made between pregnancy rate, the cancellation rate, the presence of ovarian hyperstimulation syndrome and other complications.

Results

Pregnancy rates were similar in both groups (per cycle initiated, 33.6% in the study group vs. 36.4% in the control group). No differences were found in the variables analysed in the stimulation cycle and in the number of complications between both groups, with only 4 patients being cancelled due to the risk of ovarian hyperstimulation in the study group, with no differences with the control group (3.2 vs. 5.9%).

Conclusions

In patients with a normal response prognosis, controlled ovarian stimulation with corifollitropin alpha, shows no statistically significant differences with conventional treatment, and represents a comfortable alternative for the patient, since it improves adherence to treatment in those with established normal response prognosis.